Hebestreit, Helge
,
Lands, Larry C.
Alarie, Nancy
Schaeff, Jonathan
Karila, Chantal
Orenstein, David M.
Urquhart, Don S.
Hulzebos, Erik H. J.
Stein, Lothar
Schindler, Christian
Kriemler, Susi
Radtke, Thomas
Funding for this research was provided by:
German Cystic Fibrosis Association (1402)
Swiss Society for Cystic Fibrosis (no grant number available)
Cystic Fibrosis Canada (2880)
Association Vaincre la Mucoviscidose (RC 20160501689/1/1/186)
Nederlandse Cystic Fibrosis Stichting (no grant number available)
The Swiss National Science Foundation (320030_144175)
Cystic Fibrosis Foundation (no grant number available)
Mylan Healthcare GmbH (not applicable)
Vertex Innovation Award, Vertex Pharmaceuticals (2014-01)
Edinburgh Children's Hospital Charity (2013/14/24)
Article History
Received: 4 September 2017
Accepted: 29 January 2018
First Online: 8 February 2018
Ethics approval and consent to participate
: Ethical approval was obtained from all respective ethical research committees from all participating institutions: Ethik-Kommission, Institut für Pharmakologie und Toxikologie, Würzburg, Wuerzburg, Germany; Ethik-Kommission der Medizinischen Fakultät, Ruhr Universität Bochum (RUB), Bochum, Germany; Ethik-Kommission an der Technischen Universität Dresden, Dresden, Germany; Ethik-Kommission, Medizinische Fakultät der Universität Duisburg-Essen, Essen, Germany; Ethik-Kommission der Ärztekammer Hamburg, Hamburg, Germany; Ethik-Kommission, Fachbereich Medizin Frankfurt, Goethe-Universität, Frankfurt; Germany; Ethik-Kommission, Medizinische Hochschule Hannover, Hannover, Germany; Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität, Münster, Muenster, Germany; Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität Tübingen, Tuebingen, Germany; Ländesärtzekammer Baden-Württemberg, Stuttgart, Germany; Ethik-Kommission, Landesärztekammer Rheinland-Pfalz, Mainz, Germany; Ethik-Kommission bei der Ludwig Maximilians Universität München, München, Germany; Ethik-Kommission der Medizinischen Universität Innsbruck, Innsbruck, Austria; Ethik-Kommission, Medizinische Universität Graz, Graz, Austria; Kantonale Ethik-Kommission, Kanton Zürich, Zurich, Switzerland; West of Scotland Research Ethics Service; Glasgow, UK; Comite de Protection des Personnes Ile De France III, Paris, France; Medisch Ethische Toetsingscommissie (METC) van het UMC Utrecht, Utrecht, Netherlands; Institutional Review Board for Human Use, The University of Alabama at Birmingham, Birmingham AL, US; Institutional Review Board, University of Pittsburgh, Pittsburgh, US; MUHC Research Ethics Board, Montreal, QC, Canada. The ethical commission of the Medical Faculty of the University of Wurzburg, Germany is the leading commission for this study (ref.no: 174/13). All study participants or their legal guardians, if participants are under age, will provide informed consent before any study-related procedures are performed. Participants under age will provide oral and written assent. The study protocol has been reviewed and accepted by the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) to run in ECFS-CTN sites.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.